Nothing Special   »   [go: up one dir, main page]

SE9401108D0 - Ophthalmic composition I - Google Patents

Ophthalmic composition I

Info

Publication number
SE9401108D0
SE9401108D0 SE9401108A SE9401108A SE9401108D0 SE 9401108 D0 SE9401108 D0 SE 9401108D0 SE 9401108 A SE9401108 A SE 9401108A SE 9401108 A SE9401108 A SE 9401108A SE 9401108 D0 SE9401108 D0 SE 9401108D0
Authority
SE
Sweden
Prior art keywords
amount
pct
weight
composition
polymer
Prior art date
Application number
SE9401108A
Other languages
English (en)
Swedish (sv)
Inventor
Timo Reunamaeki
Kari Lehmussaari
Eija Vartiainen
Olli Oksala
Sakari Alaranta
Esko Pohjala
Original Assignee
Leiras Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leiras Oy filed Critical Leiras Oy
Priority to SE9401108A priority Critical patent/SE9401108D0/xx
Publication of SE9401108D0 publication Critical patent/SE9401108D0/xx
Priority to BR9507438A priority patent/BR9507438A/pt
Priority to SK1239-96A priority patent/SK280492B6/sk
Priority to DE0752847T priority patent/DE752847T1/de
Priority to CZ19962865A priority patent/CZ290987B6/cs
Priority to EE9600120A priority patent/EE03661B1/xx
Priority to PCT/FI1995/000166 priority patent/WO1995026711A1/en
Priority to US08/535,037 priority patent/US5710182A/en
Priority to CN95192185A priority patent/CN1112918C/zh
Priority to PT95914362T priority patent/PT752847E/pt
Priority to EP95914362A priority patent/EP0752847B1/en
Priority to PL95316584A priority patent/PL179433B1/pl
Priority to MX9603918A priority patent/MX9603918A/es
Priority to ES95914362T priority patent/ES2161874T3/es
Priority to JP7525423A priority patent/JPH10503470A/ja
Priority to AU21389/95A priority patent/AU694497B2/en
Priority to AT95914362T priority patent/ATE202921T1/de
Priority to RU96119953A priority patent/RU2139016C1/ru
Priority to RO96-01877A priority patent/RO115409B1/ro
Priority to HU9602691A priority patent/HU223071B1/hu
Priority to KR1019960705391A priority patent/KR100365914B1/ko
Priority to DE69521686T priority patent/DE69521686T2/de
Priority to CA002186734A priority patent/CA2186734A1/en
Priority to DK95914362T priority patent/DK0752847T3/da
Priority to FI963744A priority patent/FI117921B/fi
Priority to NO19964070A priority patent/NO314434B1/no
Priority to BG100915A priority patent/BG63145B1/bg
Priority to HK98115146A priority patent/HK1013953A1/xx
Priority to GR20010401621T priority patent/GR3036763T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SE9401108A 1994-03-31 1994-03-31 Ophthalmic composition I SE9401108D0 (sv)

Priority Applications (29)

Application Number Priority Date Filing Date Title
SE9401108A SE9401108D0 (sv) 1994-03-31 1994-03-31 Ophthalmic composition I
DK95914362T DK0752847T3 (da) 1994-03-31 1995-03-29 Ophthalmisk sammensætning med nedsat viskositet
MX9603918A MX9603918A (es) 1994-03-31 1995-03-29 Composicion oftalmica con viscosidad disminuida.
JP7525423A JPH10503470A (ja) 1994-03-31 1995-03-29 減少した粘度を有する眼科治療用組成物
DE0752847T DE752847T1 (de) 1994-03-31 1995-03-29 Ophtalmische zubereitung niedriger viskosität
CZ19962865A CZ290987B6 (cs) 1994-03-31 1995-03-29 Oční přípravek se sníľenou viskozitou
EE9600120A EE03661B1 (et) 1994-03-31 1995-03-29 Vähendatud viskoossusega oftalmoloogiline kompositsioon
PCT/FI1995/000166 WO1995026711A1 (en) 1994-03-31 1995-03-29 Ophthalmic composition with decreased viscosity
US08/535,037 US5710182A (en) 1994-03-31 1995-03-29 Ophthalmic composition
CN95192185A CN1112918C (zh) 1994-03-31 1995-03-29 低粘度的眼药组合物
PT95914362T PT752847E (pt) 1994-03-31 1995-03-29 Composicao oftalmica com viscosidade reduzida
EP95914362A EP0752847B1 (en) 1994-03-31 1995-03-29 Ophthalmic composition with decreased viscosity
PL95316584A PL179433B1 (pl) 1994-03-31 1995-03-29 Kompozycja do oczu w postaci wodnego roztworu do miejscowego stosowania PL PL
BR9507438A BR9507438A (pt) 1994-03-31 1995-03-29 Composição oftálmica com viscosidade reduzida
ES95914362T ES2161874T3 (es) 1994-03-31 1995-03-29 Composicion oftalmica con viscosidad reducida.
SK1239-96A SK280492B6 (sk) 1994-03-31 1995-03-29 Očný prípravok so zníženou viskozitou
AU21389/95A AU694497B2 (en) 1994-03-31 1995-03-29 Ophthalmic composition with decreased viscosity
AT95914362T ATE202921T1 (de) 1994-03-31 1995-03-29 Ophtalmische zubereitung niedriger viskosität
RU96119953A RU2139016C1 (ru) 1994-03-31 1995-03-29 Офтальмическая композиция на основе водного раствора ионочувствительного гидрофильного полимера (варианты)
RO96-01877A RO115409B1 (ro) 1994-03-31 1995-03-29 Compozitie oftalmica cu viscozitate scazuta
HU9602691A HU223071B1 (hu) 1994-03-31 1995-03-29 Csökkentett viszkozitású szemészeti készítmény
KR1019960705391A KR100365914B1 (ko) 1994-03-31 1995-03-29 점도가감소된안약조성물
DE69521686T DE69521686T2 (de) 1994-03-31 1995-03-29 Ophtalmische zubereitung niedriger viskosität
CA002186734A CA2186734A1 (en) 1994-03-31 1995-03-29 Ophthalmic composition with decreased viscosity
FI963744A FI117921B (fi) 1994-03-31 1996-09-20 Alennetun viskositeetin omaava oftalminen koostumus
NO19964070A NO314434B1 (no) 1994-03-31 1996-09-27 Lav-viskositets oftalmisk blanding
BG100915A BG63145B1 (bg) 1994-03-31 1996-10-16 Офталмологичен състав с понижен вискозитет
HK98115146A HK1013953A1 (en) 1994-03-31 1998-12-23 Ophthalmic composition with decreased viscosity
GR20010401621T GR3036763T3 (en) 1994-03-31 2001-09-28 Ophthalmic composition with decreased viscosity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9401108A SE9401108D0 (sv) 1994-03-31 1994-03-31 Ophthalmic composition I

Publications (1)

Publication Number Publication Date
SE9401108D0 true SE9401108D0 (sv) 1994-03-31

Family

ID=20393511

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9401108A SE9401108D0 (sv) 1994-03-31 1994-03-31 Ophthalmic composition I

Country Status (27)

Country Link
US (1) US5710182A (xx)
EP (1) EP0752847B1 (xx)
JP (1) JPH10503470A (xx)
KR (1) KR100365914B1 (xx)
CN (1) CN1112918C (xx)
AT (1) ATE202921T1 (xx)
AU (1) AU694497B2 (xx)
BG (1) BG63145B1 (xx)
BR (1) BR9507438A (xx)
CA (1) CA2186734A1 (xx)
CZ (1) CZ290987B6 (xx)
DE (2) DE69521686T2 (xx)
DK (1) DK0752847T3 (xx)
EE (1) EE03661B1 (xx)
ES (1) ES2161874T3 (xx)
GR (1) GR3036763T3 (xx)
HK (1) HK1013953A1 (xx)
HU (1) HU223071B1 (xx)
MX (1) MX9603918A (xx)
NO (1) NO314434B1 (xx)
PL (1) PL179433B1 (xx)
PT (1) PT752847E (xx)
RO (1) RO115409B1 (xx)
RU (1) RU2139016C1 (xx)
SE (1) SE9401108D0 (xx)
SK (1) SK280492B6 (xx)
WO (1) WO1995026711A1 (xx)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9718568D0 (en) 1997-09-03 1997-11-05 Chauvin Pharmaceuticals Limite Compositions
AU4808000A (en) 1999-04-28 2000-11-10 Situs Corporation Drug delivery system
US6852688B2 (en) 2000-03-10 2005-02-08 University Of Florida Compositions for treating diabetic retinopathy and methods of using same
CN1638734A (zh) * 2002-02-22 2005-07-13 参天制药株式会社 微粒结膜下给药的药物释放系统
US7128928B2 (en) * 2002-02-22 2006-10-31 Pharmacia Corporation Ophthalmic formulation with novel gum composition
JP2004196787A (ja) * 2002-12-04 2004-07-15 Santen Pharmaceut Co Ltd 結膜下デポによるドラッグデリバリーシステム
EP1568359A4 (en) * 2002-12-04 2011-05-18 Santen Pharmaceutical Co Ltd DRUG DELIVERY SYSTEM HAVING SUB-CONJUNCTIVAL DEPOSIT
US7947295B2 (en) * 2003-06-13 2011-05-24 Alcon, Inc. Ophthalmic compositions containing a synergistic combination of two polymers
CA2839847C (en) * 2003-06-13 2016-03-15 Masood A. Chowhan Ophthalmic compositions containing a synergistic combination of two polymers
WO2005018608A1 (ja) * 2003-08-20 2005-03-03 Santen Pharmaceutical Co., Ltd. 微粒子テノン嚢下投与ドラッグデリバリーシステム
TWI367098B (en) * 2004-12-23 2012-07-01 Kowa Co Treating agent for glaucoma
US7862552B2 (en) 2005-05-09 2011-01-04 Boston Scientific Scimed, Inc. Medical devices for treating urological and uterine conditions
DE102005035986B4 (de) * 2005-07-28 2009-10-15 Bausch & Lomb Incorporated Steriles tropfbares mehrphasiges emulgatorfreies ophthalmisches Präparat
EP2334686B1 (en) 2008-08-28 2019-02-27 President and Fellows of Harvard College Cortistatin analogues and syntheses therof
EP2383286A1 (en) 2010-04-30 2011-11-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of retinal degenerative diseases
JP2012180346A (ja) * 2011-02-10 2012-09-20 Santen Pharmaceut Co Ltd 親水性薬物の薬物移行性を改善した水性組成物
WO2013124477A1 (en) 2012-02-24 2013-08-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of retinal degenerative diseases
SG10201808151RA (en) 2013-12-24 2018-10-30 Harvard College Cortistatin analogues and syntheses and uses thereof
EP3294298A4 (en) 2015-05-08 2018-10-17 President and Fellows of Harvard College Cortistatin analogues, syntheses, and uses thereof
WO2017004411A1 (en) 2015-07-01 2017-01-05 President And Fellows Of Harvard College Cortistatin analogues and syntheses and uses thereof
EP3340982B1 (en) 2015-08-26 2021-12-15 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
CN109475756A (zh) 2016-02-17 2019-03-15 儿童医疗中心有限公司 Ffa1(gpr40)作为神经血管生成疾病或病症的治疗标靶
MX2018016046A (es) 2016-06-27 2019-05-02 Achillion Pharmaceuticals Inc Quinazolina y compuestos indol para tratar trastornos medicos.
WO2018033854A1 (en) * 2016-08-15 2018-02-22 Santen Pharmaceutical Co., Ltd. Ophthalmic composition and a method for treating ocular hypertension and glaucoma
US9867810B1 (en) 2016-08-19 2018-01-16 Orasis Pharmaceuticals Ltd. Ophthalmic pharmaceutical compositions and uses relating thereto
KR102632860B1 (ko) 2017-03-01 2024-02-02 아칠리온 파르마세우티칼스 인코포레이티드 의학적 장애의 치료를 위한 아릴, 헤테로아릴, 및 헤테로사이클릭 약학적 화합물
PT3548000T (pt) * 2017-05-11 2021-12-10 Vyluma Inc Composiões farmacológicas com atropina
EP3773576A4 (en) 2018-03-26 2021-12-29 C4 Therapeutics, Inc. Cereblon binders for the degradation of ikaros
WO2020041301A1 (en) 2018-08-20 2020-02-27 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
CN113365617A (zh) 2018-10-16 2021-09-07 乔治亚州立大学研究基金会股份有限公司 用于医学疾病治疗的一氧化碳前药
CA3165309A1 (en) 2020-03-05 2021-09-10 Christopher G. Nasveschuk Compounds for targeted degradation of brd9
EP4288049A1 (en) * 2021-02-04 2023-12-13 Sydnexis, Inc. Ophthalmic compositions for presbyopia
EP4088713A1 (en) 2021-05-10 2022-11-16 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Ophthalmic pharmaceutical composition comprising atropine
EP4088714A1 (en) 2021-05-10 2022-11-16 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Ophthalmic pharmaceutical composition comprising atropine
CN113786380A (zh) * 2021-09-18 2021-12-14 华北制药股份有限公司 一种硝酸毛果芸香碱眼用凝胶及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6056684B2 (ja) * 1977-11-07 1985-12-11 東興薬品工業株式会社 点眼剤
US5252318A (en) * 1990-06-15 1993-10-12 Allergan, Inc. Reversible gelation compositions and methods of use
FR2678832B1 (fr) * 1991-07-10 1995-03-17 Europhta Sa Laboratoire Nouvelles compositions ophtalmiques a resorption amelioree et leurs procedes de preparation.

Also Published As

Publication number Publication date
DE69521686D1 (de) 2001-08-16
BG100915A (en) 1997-07-31
AU2138995A (en) 1995-10-23
ES2161874T3 (es) 2001-12-16
CN1112918C (zh) 2003-07-02
HK1013953A1 (en) 1999-09-17
PT752847E (pt) 2001-12-28
JPH10503470A (ja) 1998-03-31
DE69521686T2 (de) 2002-04-25
NO964070L (no) 1996-11-28
RO115409B1 (ro) 2000-02-28
HU223071B1 (hu) 2004-03-01
PL316584A1 (en) 1997-01-20
NO314434B1 (no) 2003-03-24
NO964070D0 (no) 1996-09-27
HU9602691D0 (en) 1996-11-28
SK280492B6 (sk) 2000-03-13
DE752847T1 (de) 1997-09-04
RU2139016C1 (ru) 1999-10-10
AU694497B2 (en) 1998-07-23
US5710182A (en) 1998-01-20
EP0752847A1 (en) 1997-01-15
EE9600120A (et) 1997-04-15
CN1144477A (zh) 1997-03-05
DK0752847T3 (da) 2001-10-22
ATE202921T1 (de) 2001-07-15
PL179433B1 (pl) 2000-09-29
EP0752847B1 (en) 2001-07-11
WO1995026711A1 (en) 1995-10-12
BG63145B1 (bg) 2001-05-31
GR3036763T3 (en) 2001-12-31
CA2186734A1 (en) 1995-10-12
KR100365914B1 (ko) 2003-04-16
KR970702024A (ko) 1997-05-13
BR9507438A (pt) 1997-09-16
EE03661B1 (et) 2002-04-15
CZ290987B6 (cs) 2002-11-13
CZ286596A3 (en) 1997-04-16
MX9603918A (es) 1997-04-30
SK123996A3 (en) 1997-06-04
HUT75666A (en) 1997-05-28

Similar Documents

Publication Publication Date Title
SE9401108D0 (sv) Ophthalmic composition I
SE9401109D0 (sv) Opthalmic composition II
US5945121A (en) Liposome eye drops
DE68929031T2 (de) Antimikrobielle wässerige Lösungen für die Kontaktlinsenpflege
KR960700081A (ko) 콘택트렌즈 용액 보존 시스템(preservative system for contact lens solutions)
CA2183547A1 (en) Compositions for treating defective cell functions
BR0000707A (pt) Composição de fase aquosa contìnua, utilização de pelo menos um sequestrante associado a pelo menos um neutralizante, processo de estabilização do ácido l-2- oxotiazolidina 4-carboxìlico e utilização da composição
DE3625867C2 (de) Verwendung von Tetrachlordecaoxid in der Ophthalmologie
JPS6452727A (en) Antiallergic eye drop
FI963744A (fi) Alennetun viskositeetin omaava oftalminen koostumus
AU2001242398A1 (en) Contact lens treating method and composition
JPS6217973B2 (xx)